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Purpose: Most commercially available treatment planning systems for brachytherapy operate based
on physical dose and do not incorporate fractionation or tissue-specific response. The purpose of the
study is to investigate the potential for hypofractionation in HDR brachytherapy, thereby reducing
the number of implants required.
Methods and Materials: A new treatment planning algorithm was built in order to optimize based
on tissue and fractionation specific parameters. Different fractionation schemes were considered for 6
patients, and plans were created using the new algorithm. A baseline fractionation scheme consisting
of 5 fractions was compared to hypofractionated plans of 1 to 4 fractions. The effectiveness of each
plan was evaluated using radiobiological criteria taken from GEC-ESTRO guidelines [1].
Results: The results of this study indicate that an optimization algorithm based on biological pa-
rameters has similar functionality to traditional planning methods with the additional ability to
account for fractionation effects. Using this algorithm, it was shown that plans consisting of 3 and 4
fractions have comparable target coverage with equivalent normal tissue exposure. In some specific
cases, further fractionation may present acceptable target coverage as well.
Conclusions: An algorithm based on radiobiological parameters has clinically acceptable perfor-
mance. Plans created by this optimization show that, while smaller doses per fraction result in
larger target coverage with equivalent normal tissue exposure, plans consisting of 3 or 4 fractions
are comparable and clinically viable.
I. INTRODUCTION
High dose-rate (HDR) brachytherapy treatment for
cervical cancer often consists of 5 or more fractions de-
livered over a period of several weeks [2, 3]. In con-
trast, recent trials for prostate cancer [4–7] have been
investigating the effectiveness of as few as 1 or 2 frac-
tions of HDR brachytherapy. The difference in fraction-
ation is due to the disparity in α/β between prostate
tumors and cervical tumors, where α and β are tissue-
specific radiobiological parameters [8]. Prostate tumor
tissue and normal tissue α/β = 1.5 − 3 Gy and are
considered “late-responding” tissues, while most gyne-
cological cancers have α/β = 10 Gy and are considered
“early-responding” tissues. Late responding tissues are
more efficient at repairing damage and thus smaller doses
per fraction preferentially spare normal tissue. Because
prostate cancer has a comparable α/β to normal tissue, it
does not have the same favorable reaction to lower doses
per fraction and larger number of fractions per treatment.
In contrast, cervical cancer is composed of early respond-
ing tissue and is not as capable at repairing damage in
periods between fractionation. These effects can be seen
in the classical equation for the biologically effective dose
(BED),
BED = D · RE (1)
where the RE is the relative effectiveness of a treat-
ment. For fractionated HDR brachytherapy, RE is given
by
RE = 1 +
d
α/β
, (2)
where d is the dose per fraction [9]. Eqn. (2) indicates
that, with two types of tissue, the one with a lower α/β
will result in a larger BED. In the case of gynecological
cancer, the tumor has a larger α/β than the surrounding
normal tissue, which suggests that the same physical dose
will have a larger effect in the normal tissue. This effect
can be countered by reducing the dose per fraction and
allowing more time between fractions for the tissue to
repair itself. Tumors with a high α/β will not benefit
as substantially from this treatment structure, and thus
the therapeutic ratio of the treatment will increase. This
indicates that dividing HDR brachytherapy treatments
into a larger number of fractions will lower the toxicity
to organs at risk.
However, in some cases, hypofractionation is desired
due to the increased patient comfort and lower econom-
ical impacts. Due to the non-linear nature of Eqn. (2),
physical dose cannot simply be added across fractions
and delivery techniques without the use of radiobiolog-
ical models. Some treatment planning software allows
the user to convert the final dose distribution after plan-
ning into biological dose. However, commercially avail-
able treatment planning software plans on physical dose
alone and evaluation of plans are done only after the op-
timization is finished. In order to examine whether hy-
pofractionation in cervical cancer can allow adequate tar-
get without increased normal tissue dose, a radiobiology-
based treatment planning algorithm is needed in order to
2inform the optimization of fractionation effects so that
plan parameters can be adjusted in order to compensate
for the effects discussed above.
Radiobiology-based treatment planning is less com-
monly used due to concerns such as the validity of ra-
diobiological parameters or models and increased com-
putation time. While there are concerns about the mod-
els that are able to be used, the algorithm built for this
study can easily be updated to account for changes in
these models or parameters. In addition, the computa-
tion time that is incurred by optimizing based on radio-
biological parameters is not of significant proportion due
to the efficient structure of the optimization considered
here. Therefore, the increase in time taken to find an
optimal implant is still acceptable clinically.
While it is known that radiobiological factors affect the
ability to hypofractionate HDR brachytherapy for cervi-
cal cancer, lower fractionation may be desirable clinically
[10]. Using biological parameters and a radiobiology-
based optimization, the effectiveness of various fraction-
ation schemes for 6 cervical cases were examined to de-
termine whether it is possible to achieve similar target
coverage and limitation of normal tissue toxicity for var-
ious fractionation schemes.
II. METHODS AND MATERIALS
A. Patient Demographics
The clinical standard for cervical cancer brachytherapy
at our institution is a uterine tandem and ring applicator
accompanied by two interstitial needles. Image data sets
from six patients previously treated at our clinic were
used in this study. For each patient and implant geome-
try, five fractionation schemes were studied. These plans
were created using an upgraded form of IPSA [11] that
optimizes based on biological parameters.
B. Optimization Algorithm
1. Traditional Planning
Traditional planning at our clinic uses the IPSA in-
verse planning algorithm that was developed in-house
and has been available commercially since 2004. Be-
fore constructing a dose plan, the patient obtains a CT
scan with the catheters in place, and relevant anatomical
structures and catheter positions are digitized for input
into the IPSA algorithm.
Dose points are used to control the dose distribu-
tion within the target volume and organs at risk. HDR
brachytherapy produces a steep dose gradient and results
in highly inhomogeneous dose distributions within the
target volume and nearby organs. Thus, a large number
of dose points are typically needed to control the dose
within organs near active dwell positions. In order to
account for this with minimal computation time, IPSA
distributes dose points differently along the surface of the
organs, in volumes with low doses, and volumes with high
doses. Low volume dose points are uniformly distributed
in the organ far away from the dwell positions. Together
with the surface dose points, these points ensure appro-
priate target coverage and organ sparing. In addition,
high volume dose calculation points are distributed to
control dose hotspots around dwell positions. Available
dwell positions inside the implant and within the tar-
get are assigned initial dwell times of 1 second and these
times are adjusted throughout the optimization.
After dose points and initial dwell times are assigned,
a dose rate matrix is calculated based on the distance of
each dose calculation point from every possible dwell po-
sition. The dose rate is calculated based on the equation
outlined in TG43 [12]:
D˙ij = SkΛΦan(θ, rij)g(rij)/r
2
ij , (3)
where Sk is the air kerma strength, Λ is the dose
rate constant, Φan(θ, rij) is the anisotropy function, and
g(rij) is the radial dose function. The dose rate is calcu-
lated for each dose point in all organs, and a dose rate
matrix is created. The dose distribution is found from
multiplying the dwell time t by the dose rate d due to
that source at each point. To further eliminate compu-
tation time, when an adjustment is made to the dwell
time of a source, the difference in time is multiplied by
the dose rate and this new dose is added to the existing
dose at each point,
D = D0 + (t− t0)d (4)
where t0 is the previous dwell time, and D0 is the pre-
vious dose. Thus, the entire dose distribution does not
need to be calculated for each iteration, only the differ-
ence is found and this is added to the existing matrix.
Suitable dose plans are constructed using predefined
dosimetric criteria input by the physician. A cost func-
tion is created in order to assign numerical values to the
clinical criteria. Clinical objectives are defined by a range
of doses that are acceptable for each organ and corre-
sponding penalties for dose delivered outside the range.
The parameters DL and DH define the low and high
doses that are acceptable, and wL and wH are the cor-
responding weights. For the target volume, the prescrip-
tion dose per fraction is usually used as the lower dose
constraint on the target volume. For the organs at risk,
the upper dose limit is commonly determined by a per-
centage of the penalty, typically half of the prescription
dose. The conversion from dose to penalty, p, is given by
pi =


−wL(Di − L) Di ≤ DL
0 DL < Di ≤ DH
wR(Di −R) Di > DH ,
(5)
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FIG. 1. Algorithmic steps followed by the radiobiological op-
timization used in this study.
where pi is the penalty for point i based on the dose,
Di, at that point. A total penalty is calculated for each
organ by summing the penalties over each point in an
organ:
P =
N∑
i
=
pi
N
. (6)
The cost function for the dwell time configuration of a
given iteration is the sum of the penalties for each organ.
The algorithm then systematically alters dwell times for
each position in order to minimize the total penalty using
a simulated annealing optimization engine where ideal
cooling parameters have previously been found [11].
2. Biological Planning
The radiobiological optimization used in this study al-
ters and adds several steps in the traditional optimiza-
tion. A workflow diagram of the new optimization can be
seen in Fig. 1. The patient data acquisition is consistent
between the two algorithms, but the dose criteria used
differs. In traditional panning, the dose limits are based
on physical prescription dose for one fraction. The op-
timization built for this study uses criteria based on the
entire treatment and uses biological models to determine
the effectiveness of the complete plan using all fractions.
For this study the radiobiological dose used was equiv-
alent dose in 2 Gy fractions (EQD2) which is converted
from BED using
EQD2 =
BED
1 + 2α/β
, (7)
where BED is found using Eqn. (1). The acceptable
doses DL and DH are taken from GEC-ESTRO recom-
mendations for the total amount of dose that should be
delivered across all fractions [1]. Because the doses are
given in EQD2, there is no need to change the dosimetric
criteria based on the number of fractions in a treatment.
Traditionally, the number of fractions would be decided
by a physician before optimization. The prescription dose
for each fraction would then depend on the total num-
ber of fractions so that, regardless of the fractionation
scheme, the total biological dose delivered at the end of
treatment is about the same. Because the optimization
developed in this study accounts for all fractions, individ-
ual fraction prescriptions do not need to be determined,
and the optimization finds the ideal dose per fraction so
that organs at risk are spared.
The parameters DL and DH remain constant for each
patient and fractionation scheme, and the user inputs the
number of fractions. The weights wL and wH can be ad-
justed by the physician in the same manner as before if
the dose distribution is not satisfactory after optimiza-
tion.
After all dosimetric criteria has been input, the opti-
mization assigns dwell times and dose points in the same
manner as the traditional IPSA algorithm. The dose rate
matrix is based on physical dose and is calculated us-
ing Eqn. (3). The initial physical dose distribution is
then used to create an additional biological dose distri-
bution matrix. The total dose at each point from all
dwell positions is converted into EQD2 using Eqn. (6)
and stored in the new matrix. When the physical dose is
converted to EQD2, the number of fractions is taken into
account, where the conversion assumes that the implant
and dwell time configuration will be the same for each
fraction. This matrix is then the one used to calculate
the cost function rather than the original physical dose
distribution. Penalties are calculated in the same manner
as Eqn. (4) and summed over each organ.
Based on the penalties accumulated, the algorithm
adjusts the dwell time configuration, and differences in
dwell times are calculated for each dwell position. Due to
the non-linear nature of the linear quadratic model, the
dose difference due to the change in dwell time cannot be
simply added to the previous dose distribution as is done
in the physical optimization. The dose change is added
to the physical dose distribution and the biological dose
distribution is then re-calculated from the new physical
4Biological Parameters
Organ Guideline Dose EBRT Dose
Rectum 65 Gy 45 Gy
Bladder 70 Gy 45 Gy
Bowel 65 Gy 45 Gy
CTV 85 Gy 55 Gy
TABLE 1. Biological parameters used to compare different
fractionated treatments. Recommended values were taken
from GEC-ESTRO guidelines [1].
dose distribution matrix. The process then repeats until
a maximum is located or the maximum number of itera-
tions is reached.
In order to determine the validity of this optimization,
the output of both optimizations were compared. For
the biological optimization to be properly functional, a
dose-volume histogram made from the resulting dose dis-
tribution should mirror the output of the traditional op-
timization in shape and scale. Dose-volume histograms
were created using the physical dose distribution from
both optimizations and it was seen that the two his-
tograms had similar shape and structure. Dose-volume
histograms from the original IPSA and the radiobiology-
based IPSA optimization can be seen in Fig. 2 which in-
dicates that the two optimizations produce similar, but
varying dose distributions. A small deviation in dose
distribution is evidence that the optimization adjusts for
fractionation effects; however, a similar dose distribution
to those typically seen clinically should be kept in or-
der to obtain the desired clinical results. In addition, the
dose distribution output by the physical optimization was
converted into EQD2, and this produced similar results.
This indicates that the distribution created by the bio-
logical optimization is reasonable but different, showing
that informing that optimization about biological param-
eters promotes a change in configuration.
C. Plan Evaluation
The quality of each plan was judged based on the bio-
logical dose delivered to 2cc of each organ at risk (D2cc).
While creating the plans, the weights on the organs at
risk and the target volume were adjusted so that the
dose to the organs just approached the maximum recom-
mended values. The maximum values for the organs at
risk were taken from GEC-ESTRO recommendations for
cervix cancer brachytherapy which determined that the
organs at risk should receive less than 65-70 Gy (EQD2)
after the completion of all fractions and that 90% of
the target volume should receive 85 Gy (EQD2). Total
EQD2 recommendations are given as total doses includ-
ing both external beam and brachytherapy and have not
been thoroughly investigated for either as monotherapy.
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FIG. 2. Dose-volume histogram created from physical dose
distribution using the original IPSA and radiobiology-based
IPSA optimization for case A in this study.
The focus of this study was on the dose distribution due
to brachytherapy alone, and thus a typical external beam
dose was assigned to each of the organs at risk and tar-
get. The typical doses from external beam for the organs
at risk and the target can be found in Table 1 and were
taken from GEC-ESTRO guidelines [1]. This was done
in order to ensure that the toxicity on the organs at risk
all remained under the recommended values and allowed
for consistency between the plans. For the organs at
risk that were not near the maximum recommended val-
ues, a constant toxicity was kept between fractionation
schemes.
In addition to calculating the EQD2 values, the equiv-
alent uniform biologically effective dose, or EUBED, was
compared for each case. EUBED takes into account the
inhomogeneity in dose distribution and is important for
this study due to the effect that high doses per fractions
can have on organs [13, 14]. Hot spots in tissue can
lead to higher toxicity and are more prevalent in plans
with fewer fractions. The EUBED for an entire organ
is calculated by considering the BED of each voxel and
combining each voxel to give an effective dose for the en-
tire organ. Thus, areas of high dose are taken into con-
sideration when using EUBED and can more accurately
represent the toxicity to organs at risk. The EUBED is
found using the equation from Jones and Hoban [12],
EUBED = −
1
α
ln
(
N∑
i
vie
αBEDi
)
(8)
where BEDi is the BED from each individual voxel.
The weights on each organ were adjusted to give equal
D2cc, and the EUBEDwas recorded and compared across
fractionation schemes.
The percent volume of the CTV that received 85 Gy
(EQD2) was recorded for each case and fractionation
scheme. Loss of dose to the target area is commonly
a result of organ at risk sparing in order to reduce toxi-
5Physical Dose to Target
Case 1 fraction 2 fractions 3 fractions 4 fractions 5 fractions
A 15 Gy 12 Gy 9 Gy 9 Gy 6 Gy
B 15 Gy 12 Gy 9 Gy 9 Gy 6 Gy
C 18 Gy 12 Gy 9 Gy 9 Gy 6 Gy
D 18 Gy 15 Gy 12 Gy 9 Gy 9 Gy
E 12 Gy 9 Gy 9 Gy 6 Gy 6 Gy
F 15 Gy 12 Gy 12 Gy 9 Gy 6 Gy
TABLE 2. Physical dose delivered to 90% of the target volume.
city. Thus, we examine the amount of dose that is able
to be delivered to the target while exposing the organs
at risk to the same amount of biologically effective dose
across all fractions.
III. RESULTS
The volume of the target that received the recom-
mended 85 Gy for each case across the 5 fractionation
schemes is shown in Fig. 3. In each case, as the number
of fractions increases, the target coverage also increases.
The plans with a greater number of fractions consistently
show more target coverage with the same amount of dose
to the organs at risk due to the dose-sparing effect that
was discussed in the introduction. However, for cases C
and D, the volume of target coverage is fairly flat across
all fractionation schemes, indicating that increasing the
number of fractions does not allow for substantially more
target coverage. For cases A, B, and E, the trend shows
a significant increase in target coverage corresponding to
an increase from 1 to 3 fractions. Thus, there is a con-
siderable benefit to increasing the number of fractions in
this range. In the range above 3 fractions, the increase in
target coverage substantially decreases and approaches a
flat trend. Thus, in these cases, the number of fractions
could be reduced from 5 to 3 without considerable loss
in coverage. Therefore, while 1 or 2 fractions may not be
feasible in most cases for cervical HDR brachytherapy,
fractionation schemes consisting of 3 and 4 fractions are
clinically viable. In addition, for particularly well placed
implants, it may be possible to reduce the number of
fractions even further without significant loss of target
coverage.
The EUBED for the bladder for each fraction is shown
in Fig. 4. The plans consisting of fewer fractions show
a higher EUBED that results from the higher degree of
inhomogeneity that results from hypofractionation dis-
cussed earlier. Although the EUBED increases with
fewer fractions, the increase is not of significant propor-
tion. This indicates that lower fraction plans are not suf-
fering from a much larger increase in hot spots within the
organs and that toxicity between plans should be similar.
Because each of these plans were created with the up-
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FIG. 3. Percent of CTV receiving 85 Gy versus the number
of fractions in the total treatment for each case discussed in
this study.
graded version of IPSA that optimizes based on BED
alone, prescription doses per fraction did not need to be
assigned. For reference, the equivalent prescription dose
that would have been assigned based on the dose distri-
bution is shown in Table 2. These values were found by
calculating the physical dose that was delivered to 90%
of the target volume after the dwell times and positions
were optimized based on BED.
IV. DISCUSSION
There is a desire for hypofractionated treatments for
cervical cancer due to patient experience and economical
impact [10]. If HDR brachytherapy could be reduced to
only one fraction, the treatment could become an outpa-
tient procedure, significantly reducing patient discomfort
and time. While this research has shown single fraction
HDR brachytherapy treatments are not viable in most
cases, plans consisting of fewer fractions are clinically
acceptable and can be used to reduce the number of im-
plants needed.
Using the new algorithm that was created for this
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FIG. 4. EUBED of the bladder for each fraction. Similar
structure can be seen for the other organs at risk considered.
study, physicians can plan in real time and use the infor-
mation given from the optimization to decide the num-
ber of fractions needed for a specific patient. From the
results of this study, it can be seen that the ability to de-
liver fewer fractions depends on both the quality of the
implant, and the patient-specific anatomy. In a particu-
larly well-placed implant, such as in cases C and D, the
physician could decide to schedule fewer than 5 fractions
from the results of the optimization. In the same man-
ner, for cases such as A, B, and E, the physician could
determine that 3 or more fractions are needed and sched-
ule further implants. By incorporating the biology-based
treatment planning algorithm, physicians can determine
the quality of a specific implant and use this information
to determine the appropriate number of fractions for a
given patient.
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